Pfizer and Astellas Win FDA Priority Review for Bladder Cancer Drug with Merck's Keytruda

Pfizer and Astellas have received FDA priority review for their bladder cancer treatment, Padcev, when used in combination with Merck's Keytruda, signaling a potential expedited approval process for the therapy.